MedWatch

Analyst: Bavarian's new study design ensures smooth process

New plans for Bavarian Nordic’s phase III study of its Covid-19 booster candidate ease the further development process, allowing for the overall timeline to be maintained despite a slight delay.

Photo: Sven Hoppe/AP/Ritzau Scanpix

A redesigned phase III study of Bavarian Nordic’s ABNCoV2, a booster candidate against Covid-19, makes the development process easier while maintaining the overall time plan despite delaying initiation for August, assesses Sydbank analyst Søren Løntoft Hansen.

Even so, the adjusted plans don’t surprise him:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs